TrialLeukemia2021
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
Keenan T Hartert et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
31 papers cite it
this papertrialcites it
TrialLeukemia2021
Keenan T Hartert et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.